An expert consensus statement on biomarkers of ageing for use in intervention studies.

Biomarkers of ageing serve as important outcome measures in longevity-promoting interventions. However, there is limited consensus on which specific biomarkers are most appropriate for human intervention studies. This work aimed to address this need by establishing an expert consensus on biomarkers of ageing for use in intervention studies via the Delphi method.

Intra- and inter-session reliability and repeatability of H magnetic resonance spectroscopy for determining total creatine concentrations in multiple brain regions.

Using proton magnetic resonance spectroscopy (H MRS) to determine total creatine (tCr) concentrations will become increasingly prevalent, as the role of creatine (Cr) in supporting brain health gains interest. Methodological limitations and margins of error in repeated H MRS, which often surpass reported effects of supplementation, permeate existing literature. We examined the intra- and inter-session reliability and repeatability of H MRS for determining tCr concentrations across multiple brain regions (midbrain, visual cortex and frontal cortex).

No evidence for a privileged role of global ensemble statistics in rapid scene perception: A registered replication attempt.

The nature of visual processes underlying scene perception remains a hotly debated topic. According to one view, scene and object perception rely on similar neural mechanisms, and their processing pathways are tightly interlinked. According to another, scene gist might follow a separate pathway, relying primarily on global image properties.

Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres.

Pharmacogenetic (PGx) testing can enhance drug safety, improve efficacy, and reduce the risk of toxicity. However, the implementation of PGx testing in Canadian pediatric oncology centers has been limited. To address this gap, the aim of this study was to assess the barriers and facilitators to implementing PGx testing for three oncology drugs in eight Canadian pediatric oncology centers and identify strategies that could be used to support PGx testing implementation.